Sec Form 3 Filing - Rosinack Matthew W. @ IOVANCE BIOTHERAPEUTICS, INC. - 2025-06-30

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Rosinack Matthew W. 2. Issuer Name and Ticker or Trading Symbol IOVANCE BIOTHERAPEUTICS, INC. [ IOVA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP, Finance (Int. PFO & PAO) (Last) (First) (Middle) C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100 3. Date of Earliest Transaction (MM/DD/YY) 06/30/2025 (Street) SAN CARLOS, CA94070 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 89,129 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (Right to Buy) $ 25.3 ( 2 ) 09/27/2031 Common Stock 75,000 D Restricted Stock Units ( 6 ) ( 3 ) ( 3 ) Common Stock 11,721 D Restricted Stock Units ( 6 ) ( 4 ) ( 4 ) Common Stock 38,287 D Restricted Stock Units ( 6 ) ( 5 ) ( 5 ) Common Stock 59,060 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Rosinack Matthew W. C/O IOVANCE BIOTHERAPEUTICS, INC. 825 INDUSTRIAL ROAD, SUITE 100 SAN CARLOS, CA94070 SVP, Finance (Int. PFO & PAO) Signatures /s/ Matthew William Rosinack 07/10/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes 9,089 shares of Iovance Biotherapeutics, Inc.'s (the "Issuer") common stock purchased under the Issuer's 2020 Employee Stock Purchase Plan. ( 2 )The stock option was granted on September 27, 2021. The shares underlying this option are fully vested. ( 3 )The restricted stock units ("RSUs") were granted on March 2, 2023. One-third of the RSUs vested on March 2, 2024. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter. ( 4 )The RSUs were granted on March 1, 2024. One-third of the RSUs vested on March 1, 2025. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter. ( 5 )The RSUs were granted on March 5, 2025. One-third of the RSUs will vest on March 5, 2026. The remaining RSUs will vest in eight equal quarterly installments thereafter. ( 6 )Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks: On June 30, 2025, Matthew William Rosinack was appointed as the Issuer's interim Principal Financial Officer and Principal Accounting Officer. Mr. Rosinack has served as the Issuer's Senior Vice President, Finance since September 2021.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.